Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.40 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856050 | 0.88 | SLC6A9 (0.52) | SLC6A9PTGESNPFFR1NPFFR2P2RX7 | |
| SCHEMBL2857884 | 0.87 | ALDH1A1 (0.44) | SLC6A9NPFFR1NPFFR2ALDH1A1HSD11B1 | |
| SCHEMBL2857262 | 0.83 | P2RX7 (0.44) | SLC6A9NPFFR1NPFFR2P2RX7ALDH1A1 | |
| SCHEMBL5355428 | 0.80 | NPFFR1 (0.44) | NPFFR1NPFFR2P2RX7ALDH1A1MEN1 | |
| SCHEMBL5362779 | 0.80 | NPC1 (0.43) | SLC6A9NPFFR1NPFFR2P2RX7 | |
| SCHEMBL2858583 | 0.77 | P2RX7 (0.46) | NPFFR1NPFFR2P2RX7ALDH1A1MEN1 | |
| SCHEMBL2861616 | 0.75 | LMNA (0.58) | SLC6A9NPFFR1NPFFR2P2RX7ALDH1A1 | |
| SCHEMBL2861400 | 0.75 | NPC1 (0.53) | SLC6A9NPFFR1NPFFR2ALDH1A1GAA | |
| SCHEMBL2856026 | 0.74 | MEN1 (0.65) | P2RX7ALDH1A1TP53MEN1KMT2A | |
| SCHEMBL5351381 | 0.74 | ALDH1A1 (0.45) | NPFFR1NPFFR2ALDH1A1HSD11B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | SLC6A9 1701/4885PTGES 1828/4885NPFFR1 1718/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | SLC6A9 1701/4885PTGES 1828/4885NPFFR1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.